# Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

> **NCT04107142** · PHASE1 · UNKNOWN · sponsor: **CytoMed Therapeutics Pte Ltd** · enrollment: 10 (estimated)

## Conditions studied

- Colorectal Cancer
- Triple Negative Breast Cancer
- Sarcoma
- Nasopharyngeal Carcinoma
- Prostate Cancer
- Gastric Cancer

## Interventions

- **BIOLOGICAL:** Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell

## Key facts

- **NCT ID:** NCT04107142
- **Lead sponsor:** CytoMed Therapeutics Pte Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2019-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04107142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04107142, "Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04107142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*